/ /

  • linkedin
  • Increase Font
  • Sharebar

    Stargardt’s disease treatment gains orphan designation


    Doylestown, PA—Makindus has received orphan designation for its lead product, MI-100, from the FDA’s Office of Orphan Products Development for the treatment of Stargardt’s disease.

    “The FDA’s approval for our orphan drug designation application for (our Stargardt’s disease treatment) is a key milestone for the company and we look forward to initiating our phase III confirmatory trial early next year,” said Manohar Katakam, president and chief executive officer of Makindus.

    The company acquired intellectual property and associated clinical data supporting multiple ocular indications through a licensing deal that was closed in 2013.


    For more articles in this issue of Ophthalmology Times eReport, click here.



    To receive weekly clinical news and updates in ophthalmology, subscribe to the Ophthalmology Times eReport.

    New Call-to-action


    You must be signed in to leave a comment. Registering is fast and free!

    All comments must follow the ModernMedicine Network community rules and terms of use, and will be moderated. ModernMedicine reserves the right to use the comments we receive, in whole or in part,in any medium. See also the Terms of Use, Privacy Policy and Community FAQ.

    • No comments available


    View Results